肺动脉高血压治疗方法对右心室功能有有益影响-临床前研究
André Balsa1, Rui Adão1,2,3, Carmen Brás-Silva1,4
1Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
International journal of molecular sciences
|November 14, 2023
概括
这次对肺高血压 (PH) 和右心室 (RV) 功能障碍模型的审查发现,许多药物在动物中表现出心脏保护作用. 标准化研究方法可以改善将这些发现转化为PH的人类临床试验.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 研究中的动物模型.
背景情况:
- 肺高血压 (PH) 是一种影响肺血管的渐进性疾病,右心室 (RV) 功能是关键的预后因素.
- 目前用于PH研究的动物模型往往无法有效地转化为人类临床试验.
- 在PH模型和肺动脉带化 (PAB) 模型中研究孤立的RV功能障碍的干预是至关重要的.
研究的目的:
- 审查在PH和PAB动物模型上测试的干预措施.
- 评估PH和PAB模型之间的结果一致性.
- 确定正在研究PH的药物的潜在心脏保护作用.
主要方法:
- 对对PH和PAB动物模型进行干预测试的研究进行系统审查.
- 对肺血管血动力学和RV结构/功能药物影响的分析.
- 对不同模型之间的结果进行比较,并识别方法变化.
主要成果:
- 在PH模型和PAB动物的结果之间观察到高一致性 (73.1%).
- 许多测试药物改善了PH模型中的肺血管血动力学和PAB动物中的RV功能.
- 特定的药物如马西坦,西尔代纳菲尔和塔达拉菲尔在PAB模型中显示出有限的效果,尽管在PH模型中有效.
结论:
- 许多正在研究PH的药物在动物模型中表现出心脏保护作用,表明人类潜在的治疗价值.
- 研究中的重大方法差异 (治疗时间,持续时间,麻醉) 阻碍了结果的可比性.
- 在PH和PAB模型中标准化研究方法对于改善研究结果转化为临床试验至关重要.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
233
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
233
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163